The rational of a fixed combination of benzoyl peroxide and niacinamide in the treatment of acne vulgaris: A narrative review

From Top Italian Scientists Journal
Published
March 1, 2024
Title
The rational of a fixed combination of benzoyl peroxide and niacinamide in the treatment of acne vulgaris: A narrative review
Authors
Massimo Milani, Francesca Colombo
DOI
10.62684/VHXP5577
Keywords
Acne; Rosacea; Benzoyl Peroxide; Niacinamide; Fixed combination
Downloads
Download PDF
Download PDF

Massimo Milani(a), Francesca Colombo(b)

(a) Cantabria Labs Difa Cooper Medical Department, Caronno Pertusella (VA), Via Milano 160; Italy, massimo.milani@difacooper.com

(b) Cantabria Labs Difa Cooper Medical Department, Caronno Pertusella (VA), Via Milano 160; Italy, francesca.colombo@difacooper.com

Abstract

Acne vulgaris (AV) in a common skin disease affecting mainly adolescents but could be present also in adult subjects. AV is characterized by the presence of non-inflammatory (comedons) and inflammatory (papules, pustules, cysts, and nodules) lesions affecting sebaceous glands rich regions like the face, back, shoulder and thorax. A central pathogenetic role of AV lesions seems played by Cutibacterium acnes, especially some phylotypes (i.e. C. acne IA1) able to induce an inflammatory response at the level of sebaceous glands. Other important pathogenetic factors of AV are the adrogen-driven increase of sebum production and the process of hyperkeratinisation of the infundibulum. The first line treatment of AV is in general done using monotherapy with antibacterial agents like benzoyl peroxide (BPO) and hydrogen peroxide or topical retinoid molecules. These two classes of drugs could interfere with C. acnes growth (BPO) and with keratinocytes proliferation (retinoid). Fixed combination of BPO and retinoid molecules are commonly used in mild to moderate forms of AV. However, both BPO and retinoids could be nor well tolerated especially during the first weeks of treatment causing skin irritation erythema and and dryness. Both BPO and topical retinoids could interfere with the skin barrier function. During BPO treatment the Trans epidermal water loss (TEWL) a marker of skin barrier function, increase significantly supporting the fact that BPO alters this function. Niacinamide is a potent anti-inflammatory molecule able to preserve the skin barrier function. Niacinamide has shown to be effective in AV with inflammatory lesions. There is a strong rationale for the development of a topical product formed by fixed combination of BPO and niacinamide for the first-line treatment of mild to moderate AV but also in the treatment of papulopustular rosacea. In this narrative review we discuss the rational of the combination and the first clinical data of this product as first line AV and rosacea treatment strategy.

Declarations

Conflict of Interest

The Authors declare that there is no conflict of interest.

References

  1. WILLIAMS, Hywel C.; DELLAVALLE, Robert P.; GARNER, Sarah. Acne vulgaris. The Lancet, 2012, 379.9813: 361-372.
  2. ZAENGLEIN, Andrea L. Acne vulgaris. New England Journal of Medicine, 2018, 379.14: 1343-1352.
  3. DRÉNO, Brigitte, et al. Cutibacterium acnes (Propionibacterium acnes) and acne vulgaris: a brief look at the latest updates. Journal of the European Academy of Dermatology and Venereology, 2018, 32: 5-14.
  4. BEYLOT, C., et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. Journal of the European Academy of Dermatology and Venereology, 2014, 28.3: 271-278.
  5. LI, Xinchao, et al. A review of the role of sebum in the mechanism of acne pathogenesis. Journal of cosmetic dermatology, 2017, 16.2: 168-173.
  6. JU, Qiang; ZOUBOULIS, Christos C.; XIA, Longqing. Environmental pollution and acne-chloracne. Dermato-endocrinology, 2009, 1.3: 125-128.
  7. THIBOUTOT, Diane; DEL ROSSO, James Q. Acne vulgaris and the epidermal barrier: is acne vulgaris associated with inherent epidermal abnormalities that cause impairment of barrier functions? Do any topical acne therapies alter the structural and/or functional integrity of the epidermal barrier?. The Journal of clinical and aesthetic dermatology, 2013, 6.2: 18.
  8. POWELL, Frank C. Rosacea. New England Journal of Medicine, 2005, 352.8: 793-803.
  9. VAN ZUUREN, Esther J. Rosacea. New England Journal of Medicine, 2017, 377.18: 1754-1764.
  10. CULP, Brittney; SCHEINFELD, Noah. Rosacea: a review. Pharmacy and Therapeutics, 2009, 34.1: 38.
  11. THIBOUTOT, Diane, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. Journal of the American Academy of Dermatology, 2009, 60.5: S1-S50.
  12. MUSUMECI, M. L., et al. Topical treatment of acne vulgaris: A review. Giornale Italiano di Dermatologia e Venereologia, 2005, 140.6: 713-722.
  13. FARES, Hani M.; CHATTERJEE, Suzanne; HAYWARD, Marshall. In vitro permeation and irritation of benzoyl peroxide-containing products. International journal of pharmaceutics, 1996, 133.1-2: 215-222.
  14. DE LUCAS, Raúl, et al. Adherence to drug treatments and adjuvant barrier repair therapies are key factors for clinical improvement in mild to moderate acne: the ACTUO observational prospective multicenter cohort trial in 643 patients. BMC dermatology, 2015, 15: 1-6.
  15. TWO, Aimee M., et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. Journal of the American Academy of Dermatology, 2015, 72.5: 761-770.
  16. BRENEMAN, Debra, et al. Double‐blind, randomized, vehicle‐controlled clinical trial of once‐daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea. International journal of dermatology, 2004, 43.5: 381-387.
  17. FARRISA, Mamina Tureganoa Patricia. Cosmeceuticals for Acne and Rosacea. Cosmeceuticals, 2021, 82.
  18. GENG, Ryan; BOURKAS, Adrienn N.; SIBBALD, R. Gary. Rosacea: Clinical Aspects and Treatments. Advances in Skin & Wound Care, 2023, 36.12: 626-634.
  19. DRAELOS, Zoe Diana, et al. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. CUTIS-NEW YORK-, 2005, 76.2: 135.
  20. VALACCHI, Giuseppe, et al. Effect of benzoyl peroxide on antioxidant status, NF-κB activity and interleukin-1α gene expression in human keratinocytes. Toxicology, 2001, 165.2-3: 225-234.
  21. WEBER, Stefan U., et al. Topical α-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. Free Radical Biology and Medicine, 2003, 34.2: 170-176.
  22. MILANI, M. Acne, anti-acne therapies and epidermal barrier functions: the role of adjuvant treatments. OA Dermatology, 2013, 1.1: 4.
  23. MATTS, Paul J.; OBLONG, John E.; BISSETT, Donald L. A review of the range of effects of niacinamide in human skin. Int Fed Soc Cosmet Chem Mag, 2002, 5.4: 285-289.
  24. ROLFE, Heidi M. A review of nicotinamide: treatment of skin diseases and potential side effects. Journal of cosmetic dermatology, 2014, 13.4: 324-328.
Retrieved from ‘https://journal.topitalianscientists.org/index.php?title=The_rational_of_a_fixed_combination_of_benzoyl_peroxide_and_niacinamide_in_the_treatment_of_acne_vulgaris_A_narrative_review&oldid=1246’